XOMA acquires LadRx royalty/milestone rights for arimoclomol and aldoxorubicin for $5M upfront

XOMA Royalty Corp

Acquired 100% of LadRx's royalty and milestone rights for arimoclomol (NPC) and aldoxorubicin (ImmunityBio).
Paid $5M upfront; additional milestone payments of up to $6M may be required.
Arimoclomol rights: $52.6M net milestones and mid-single-digit royalty from Zevra.
Aldoxorubicin rights: mid-single-digit to mid-teens royalties and up to $343M milestones from ImmunityBio.
Agreements include customary covenants, representations, and indemnification.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

XOMA Royalty Corp entered into Assignment and Assumption Agreement with LadRx Corporation valued at $5 million upfront, up to $6 million in potential milestone payments (effective 2023-06-21).

Action: entry
Agreement: license
Counterparty: LadRx Corporation
Value: $5 million upfront, up to $6 million in potential milestone payments
Effective: 2023-06-21

Exact text from the filing

On June 21, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) and a Royalty Purchase Agreement (the “Royalty Purchase Agreement” and together with the Assignment Agreement, the “Agreements”) with LadRx Corporation (“LadRx”), a Delaware corporation.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

XOMA Royalty Corp entered into Royalty Purchase Agreement with LadRx Corporation valued at $5 million upfront, up to $6 million in potential milestone payments (effective 2023-06-21).

Action: entry
Agreement: license
Counterparty: LadRx Corporation
Value: $5 million upfront, up to $6 million in potential milestone payments
Effective: 2023-06-21

Exact text from the filing

On June 21, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) and a Royalty Purchase Agreement (the “Royalty Purchase Agreement” and together with the Assignment Agreement, the “Agreements”) with LadRx Corporation (“LadRx”), a Delaware corporation.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-23-171784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.